Literature DB >> 16217061

MRI as a marker for disease heterogeneity in multiple sclerosis.

B Bielekova1, N Kadom, E Fisher, N Jeffries, J Ohayon, N Richert, T Howard, C N Bash, J A Frank, L Stone, R Martin, G Cutter, H F McFarland.   

Abstract

BACKGROUND: Whereas recent data from imaging studies challenge the prevailing notion that multiple sclerosis (MS) is purely an inflammatory disease, pathologic studies suggest differences in the disease processes between individual patients with MS. The ability to dissect the pathophysiologic disease heterogeneity, if it indeed exists, by methodologies that can be applied in vivo is important both for the development of new therapeutics and for the ability to identify the optimal therapy for an individual patient.
OBJECTIVE: To design a stratification algorithm for patients with MS based on accepted MRI measurements reflective of inflammation and axonal damage/tissue loss and to assess if such MS subgroups retain their intergroup differences long term.
METHODS: Mathematical modeling was used to select three discriminatory MRI measures for clinical outcome based on the cross-sectional analysis of 71 patients with untreated MS and tested general applicability of the stratification scheme on the independent longitudinal cohort of 71 MS patients.
RESULTS: By consecutive employment of MRI measures reflective of inflammation and tissue loss, the authors were able to separate MS patients into four clinically meaningful subgroups. The analysis of the longitudinal confirmatory cohort demonstrated persistence of the intergroup differences in selected MRI measures for 8 years.
CONCLUSIONS: The inflammatory activity and destructiveness of the multiple sclerosis process are to some degree independent of each other, and the successive evaluation of both of these variables can strengthen prediction of clinical outcome in individual patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16217061     DOI: 10.1212/01.wnl.0000178984.30534.f9

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  Brain volume and diffusion markers as predictors of disability and short-term disease evolution in multiple sclerosis.

Authors:  P G Sämann; M Knop; E Golgor; S Messler; M Czisch; F Weber
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-01       Impact factor: 3.825

2.  Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.

Authors:  Mika Komori; Andrew Blake; Mark Greenwood; Yen Chih Lin; Peter Kosa; Danish Ghazali; Paige Winokur; Muktha Natrajan; Simone C Wuest; Elena Romm; Anil A Panackal; Peter R Williamson; Tianxia Wu; Bibiana Bielekova
Journal:  Ann Neurol       Date:  2015-04-16       Impact factor: 10.422

3.  Lack of mitochondrial DNA deletions in lesions of multiple sclerosis.

Authors:  Andrei Blokhin; Tamara Vyshkina; Samuel Komoly; Bernadette Kalman
Journal:  Neuromolecular Med       Date:  2008       Impact factor: 3.843

4.  Novel composite MRI scale correlates highly with disability in multiple sclerosis patients.

Authors:  Peter Kosa; Mika Komori; Ryan Waters; Tianxia Wu; Irene Cortese; Joan Ohayon; Kaylan Fenton; Jamie Cherup; Tomas Gedeon; Bibiana Bielekova
Journal:  Mult Scler Relat Disord       Date:  2015-08-28       Impact factor: 4.339

5.  Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus.

Authors:  Tamara Vyshkina; Andrew Sylvester; Saud Sadiq; Eduardo Bonilla; Jeff A Canter; Andras Perl; Bernadette Kalman
Journal:  Clin Immunol       Date:  2008-08-16       Impact factor: 3.969

Review 6.  Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.

Authors:  Harald Hegen; Michael Auer; Florian Deisenhammer
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

Review 7.  Emerging therapies for multiple sclerosis.

Authors:  Paolo A Muraro; Bibiana Bielekova
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 8.  Progressive multiple sclerosis.

Authors:  Monika Bradl; Hans Lassmann
Journal:  Semin Immunopathol       Date:  2009-11       Impact factor: 9.623

9.  CCL genes in multiple sclerosis and systemic lupus erythematosus.

Authors:  Tamara Vyshkina; Andrew Sylvester; Saud Sadiq; Eduardo Bonilla; Andras Perl; Bernadette Kalman
Journal:  J Neuroimmunol       Date:  2008-07-03       Impact factor: 3.478

10.  'Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis.

Authors:  Lorena Lorefice; G Coghe; G Fenu; M Porta; G Pilloni; J Frau; F Corona; V Sechi; M A Barracciu; M G Marrosu; M Pau; E Cocco
Journal:  J Neurol       Date:  2017-09-11       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.